In today’s recent session, 3.34 million shares of the Novabay Pharmaceuticals Inc (AMEX:NBY) have been traded, and its beta is 2.03. Most recently the company’s share price was $0.07, and it changed around -$0.01 or -10.44% from the last close, which brings the market valuation of the company to $2.66M. NBY at last check was trading at a discount to its 52-week high of $1.95, offering almost -2685.71% off that amount. The share price’s 52-week low was $0.07. We note from Novabay Pharmaceuticals Inc’s average daily trading volume that its 3-month average coming to 3.50 million.
Novabay Pharmaceuticals Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 4 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 0 recommended NBY as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight. Novabay Pharmaceuticals Inc is expected to report earnings per share of -$0.15 for the current quarter.
Novabay Pharmaceuticals Inc (AMEX:NBY) trade information
Instantly NBY has been showing red trend so far today with a performance of -10.44% on intraday trading today. The performance over the last five days has remained in the red territory. The company’s shares are currently down -63.82% year-to-date, but still down -9.45% over the last five days. On the other hand, Novabay Pharmaceuticals Inc (AMEX:NBY) is -46.21% down in the 30-day period.
Novabay Pharmaceuticals Inc (NBY) estimates and forecasts
Novabay Pharmaceuticals Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -80.06 percent over the past six months and at a 87.76% annual growth rate that is well above the industry average of 10.20%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 82.40% in revenue this quarter, and will report an increase of 92.90% in the next quarter. The year-over-year growth rate is expected to be 0.50%, up from the previous year.
Consensus estimates provided by 2 financial analysts predict the company will bring in an average of $3.28 million in revenue for the current quarter. 2 analysts expect Novabay Pharmaceuticals Inc to make $3.58 million in revenue for the quarter ending Jun 2024. The company’s sales for the same quarters a year ago were $3.2 million and -$ respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 2.50%.
